8-K: Biofrontera Inc. Announces Record Fiscal Year 2024 Financial Results

Biofrontera Inc. reports record total revenues of $37.3 million for fiscal year 2024, a 9.5% increase from the previous year.

Summary

• Biofrontera Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• Total revenues for 2024 reached a record $37.3 million, reflecting a 9.5% increase from $34.1 million in 2023.
• Q4 2024 revenues grew by 18.5% compared to Q4 2023.
• The growth was primarily driven by increases in Ameluz sales volume and unit price, as well as the successful launch of the RhodoLED XL Lamp.
• Total SG&A costs for 2024 were $33.8 million, down from $39.1 million in 2023.
• Total operating expenses for the year decreased by approximately 3.9% to $54.5 million.
• Cash and cash equivalents stood at $5.9 million as of December 31, 2024, compared to $1.3 million at the end of 2023.
• The transfer price of Ameluz was reduced from 50% to 25% for all purchases through 2025 due to restructured agreements with Biofrontera AG.
• The company placed 52 RhodoLED XL lamps in Q4 and 100 since the launch in June 2024.
• Biofrontera obtained FDA approval to use up to three tubes of Ameluz per treatment.
• A Phase 3 study of Ameluz-PDT for superficial basal cell carcinoma achieved highly statistically significant results.
• The company created Biofrontera Discovery GmbH and transferred all clinical trial activities with Ameluz in the USA to this new entity as of June 1, 2024.
• Patient recruitment was accelerated in Phase 3 and Phase 2 studies for actinic keratosis and acne, respectively.
• A Phase 1 pharmacokinetics study was initiated as requested by the FDA for approval of treatment of AK on extremities and trunk.
• Net loss for 2024 was $(17.8) million, or $(3.22) per diluted share, compared with a net loss of $(20.1) million, or $(13.02) per share, for 2023.
• Adjusted EBITDA was negative $15.3 million for 2024 compared with negative $19.5 million for 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to record revenues and improved financial metrics, but tempered by the ongoing net losses and negative EBITDA. The company is making progress, but still has financial challenges to overcome.

Positives

• Record total revenues of $37.3 million for 2024, a 9.5% increase from 2023.
• Q4 2024 revenue growth of 18.5% compared to Q4 2023.
• Decrease in SG&A costs from $39.1 million in 2023 to $33.8 million in 2024.
• Increase in cash and cash equivalents from $1.3 million at the end of 2023 to $5.9 million as of December 31, 2024.
• Reduction in the transfer price of Ameluz from 50% to 25% for purchases through 2025.
• Successful placement of 100 RhodoLED XL lamps since launch.
• FDA approval for using up to three tubes of Ameluz per treatment.
• Statistically significant results in Phase 3 study of Ameluz-PDT for superficial basal cell carcinoma.

Negatives

• Net loss for 2024 was $(17.8) million, although this is an improvement from the $(20.1) million loss in 2023.
• Adjusted EBITDA was negative $15.3 million for 2024, compared to negative $19.5 million for 2023.
• Net income (loss) for the fourth quarter of 2024 was $(1.4) million, or $(0.19) per share, vs. net income of $3.5 million, or $1.65 per share, for the prior-year quarter, with all per-share figures on a split-adjusted basis, driven by the gain on legal settlement recognized in 2023.

Risks

• The company's ability to achieve and sustain profitability is uncertain.
• The company faces competition in selling its licensed products.
• The company's ability to expand, manage, and maintain its direct sales and marketing organizations is subject to financing availability.
• Changes in the relationship with licensors could impact the business.
• The company's actual financial results may vary significantly from forecasts.
• The company's estimates regarding operating losses, future revenues, and capital requirements are subject to uncertainty.
• Market risks exist regarding consolidation and group purchasing organizations in the healthcare industry.
• Healthcare providers' willingness to purchase licensed products depends on coverage, reimbursement, and pricing from third-party payors.
• Product quality issues or defects could harm the business.
• The company faces potential product liability claims.
• The company's ability to maintain compliance with Nasdaq listing standards is uncertain.
• The company's ability to comply with the requirements of being a public company is subject to risk.
• The progress, timing, and completion of research, development, and clinical trials are uncertain.
• The company's licensors' ability to obtain and maintain regulatory approvals is uncertain.
• Global disruptions in supply chains could impact the company's ability to obtain and distribute its licensed products.
• Uncertainties are inherent in the initiation and conduct of clinical trials.
• The market opportunity for Ameluz in combination with BF-RhodoLED may not be consistent with the company's expectations.
• The company's ability to retain and hire key personnel is subject to risk.
• The sufficiency of cash resources and the need for additional financing are uncertain.

Future Outlook

Biofrontera has refocused its strategy for 2025 to support current customers in improving their efficiency in delivering PDT services and making it easier for new customers to offer this treatment option. The company is also continuing to invest in training and development and has accelerated its clinical development program.

Management Comments

• Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated, 2024 was a very exciting year for us and lays the groundwork for continued growth and expansion.
• He further added Lastly, we have increased efforts in our clinical development program which has led to the achievement of several key milestones over the last nine months.

Industry Context

Biofrontera operates in the biopharmaceutical industry, specializing in dermatological products and photodynamic therapy (PDT). The company's focus on commercializing Ameluz with the RhodoLED lamp series for treating actinic keratosis aligns with the growing demand for non-invasive skin cancer treatments. The successful launch of the RhodoLED XL lamp and FDA approval for increased Ameluz dosage position the company favorably in the market.

Comparison to Industry Standards

• Comparing Biofrontera's revenue growth of 9.5% to other dermatology-focused biopharmaceutical companies, such as Galderma or Almirall, provides context on its market performance.
• Galderma, a major player in the dermatology space, has shown consistent growth in recent years, driven by its diverse product portfolio.
• Almirall, another European company specializing in dermatology, has also reported steady growth, focusing on innovative treatments for skin conditions.
• Biofrontera's focus on PDT and its Ameluz product differentiates it from companies with broader dermatology portfolios, such as Allergan (now part of AbbVie), which offers a wide range of aesthetic and therapeutic dermatology products.
• The reduction in SG&A expenses and the increase in cash reserves are positive indicators, suggesting improved financial management compared to industry peers.

Stakeholder Impact

• Shareholders will likely react positively to the record revenues and improved financial metrics.
• Employees may benefit from the company's continued investment in training and development.
• Customers will benefit from improved PDT services and easier access to treatment options.
• Suppliers may see increased demand for products and services.
• Creditors may view the company as a lower credit risk due to improved financial performance.

Next Steps

• Continue supporting current customers in improving their efficiency in delivering PDT services.
• Make it easier for new customers to start offering PDT treatment options.
• Continue investing in training and development.
• Continue clinical development program to expand the label to include not only face and scalp but also the trunk and extremities.
• Concluding patient recruitment in phase 2 acne study.

Key Dates

Keywords

Biofrontera, Ameluz, RhodoLED XL Lamp, Financial Results, Dermatology, PDT, Actinic Keratosis, Skin Cancer, Revenue, EBITDA